S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73%
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai MicuRx Pharmaceutical Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Net Issuance of Debt
ÂĄ227.8k
CAGR 3-Years
-67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Issuance of Debt
ÂĄ2.5B
CAGR 3-Years
9%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Issuance of Debt
-ÂĄ164.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Issuance of Debt
ÂĄ38m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Issuance of Debt
ÂĄ358.7m
CAGR 3-Years
N/A
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
227.8k CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Net Issuance of Debt amounts to 227.8k CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
-67%

Over the last year, the Net Issuance of Debt growth was -100%. The average annual Net Issuance of Debt growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been -67% over the past three years .

Back to Top